Lucie Broskevicova

Ostrava, MO, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Anti-BCMA immunotherapies deplete plasmacytoid dendritic cells and impair antiviral immunity in multiple myeloma.

Anti-BCMA immunotherapies deplete plasmacytoid dendritic cells and impair antiviral immunity in multiple myeloma.

Journal: HemaSphere

Published: May 20, 2026

Teclistamab in relapsed/refractory Waldenström macroglobulinemia

Teclistamab in relapsed/refractory Waldenström macroglobulinemia

Journal: Haematologica

Published: April 28, 2026

Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma.

Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma.

Journal: HemaSphere

Published: June 21, 2025

Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor Microenvironment.

Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor Microenvironment.

Journal: Blood cancer discovery

Published: May 15, 2025

Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.

Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.

Journal: Blood

Published: April 14, 2025

Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs.

Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs.

Journal: Blood

Published: April 14, 2025

OMIP-117: 40-Parameter/37-Color Spectral Cytometry Panel for Robust Immunoprofiling of Human Lymphoid Subsets in Cancer Patients.

OMIP-117: 40-Parameter/37-Color Spectral Cytometry Panel for Robust Immunoprofiling of Human Lymphoid Subsets in Cancer Patients.

Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology

Published: January 08, 2025

Level of Clonal Plasma Cells in Hematopoietic Cell Autografts Reflects the Pre-Transplant Bone Marrow Minimal Residual Disease in Multiple Myeloma Patients.

Level of Clonal Plasma Cells in Hematopoietic Cell Autografts Reflects the Pre-Transplant Bone Marrow Minimal Residual Disease in Multiple Myeloma Patients.

Journal: American journal of hematology

Published: November 04, 2024

Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.

Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.

Journal: Leukemia

Published: December 12, 2023

Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy.

Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy.

Journal: British journal of haematology

Published: August 06, 2023

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.

Journal: Leukemia

Published: April 24, 2021

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine.

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine.

Journal: Blood advances

Published: November 23, 2020

Showing 1-12 of 13

Last Updated: 09/26/2026